Company intelligence / Profile preview
Genocea Biosciences
Cambridge, Massachusetts, United States
- Ownership
- Private
- Employees
- ~74
- Development stage
- Other
01
Overview
Genocea advanced two clinical programs to Phase 1/2a—GEN-011 (adoptive T cell therapy for solid tumors) and GEN-009 (neoantigen vaccine for cancer); both leveraged ATLAS to identify individualized immunogenic targets. The company did not reach commercialization and liquidated assets in 2023 following bankruptcy.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- T cell therapyVaccineSynthetic long peptide (SLP) vaccineCell therapySmall molecule
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Academic institutionsLux Capital
Beyond the preview
Go deeper on Genocea Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Genocea Biosciences.